Pegcetacoplan | Aplastic Anemia & MDS International Foundation Return to top.

Pegcetacoplan

Brand name: 
EMPAVELI
Bone Marrow Disease(s): 
  • paroxysmal nocturnal hemoglobinuria (PNH)

EMPAVELI is the first PNH treatment that binds to compliment protein C3. It was approved by the Food and Drug Administration in May 2021 for treating adult patients with paroxysmal nocturnal hemoglobinuria (PNH). EMPAVELI is given by infusion under the skin (subcutaneously) into your stomach (abdomen), back of upper arms, hips, or thighs using an infusion pump.

AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any drug, treatment or therapy listed on this website. Some therapies listed on our site are considered experimental for the treatment of bone marrow failure diseases. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding any therapy, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Share with addtoany.com.